Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Receptor-selective mutants of tumour necrosis factor in the therapy of cancer: preclinical studies.

Circulatory shock - 1 Aug 1994

Brouckaert P, Ameloot P, Cauwels A, Everaerdt B, Libert C, Takahashi N, Van Molle W, Fiers W

Abstract excerpt

The use of TNF-mutants that are selective agonists of the TNF-R55 is one strategy that is being explored to broaden the therapeutic margin of TNF. Several problems still have to be overcome before they can be used in clinical trials. Regarding the sensitizing effect of some infections and some tumours, we identified IFN-gamma as a mediator in BCG- but not in tumour-induced sensitization. In both models, the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, CD
Share to Drug Tolerance
Share to TNF gene

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasms, Experimental

Share to Receptors, Tumor Necrosis Factor

Share to Tumor Necrosis Factor-alpha

Source

Identifiers

PMID: 7895324

Genes

TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Receptor-selective mutants of tumour necrosis factor in the therapy of cancer: preclinical studies.PMID 7895324Read ↗

Phenotypic analysis of TNFR1-deficient mice and characterization of TNFR1-deficient fibroblasts in vitro.Semantic proximity Read ↗

Biological activity of mutants of human tumour necrosis factor-alpha.Semantic proximity Read ↗

Cell-type-restricted anti-cytokine therapy: TNF inhibition from one pathogenic source.Semantic proximity Read ↗

An Attenuated Targeted-TNF Localizes to Tumors In Vivo and Regains Activity at the Site of Disease.Semantic proximity Read ↗

Treatment of TNF mediated diseases by selective inhibition of soluble TNF or TNFR1Semantic proximity Read ↗

Production and characterization of receptor-specific TNF muteins.Semantic proximity Read ↗

Dissociation of TNF-alpha cytotoxic and proinflammatory activities by p55 receptor- and p75 receptor-selective TNF-alpha mutants.Semantic proximity Read ↗

Creation of an improved mutant TNF with TNFR1-selectivity and antagonistic activity by phage display technology.Semantic proximity Read ↗

A novel tumor necrosis factor-alpha mutant with significantly enhanced cytotoxicity and receptor binding affinity.Semantic proximity Read ↗

Tumor necrosis factor receptor 2 plays a minor role for mycobacterial immunity.Semantic proximity Read ↗

Analysis of human tumour necrosis factor receptor 1 dominant-negative mutants reveals a major region controlling cell surface expression.Semantic proximity Read ↗

Inhibition of tumor necrosis factor-induced phenotypes by short intracellular versions of latent membrane protein-1.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.